FrancophonIA/ELRC3.0 huggingface dataset:
English: Bosutinib should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Slovenian: Zdravljenje z bosutinibom je treba trajno prekiniti pri bolnikih, pri katerih se med zdravljenjem pojavi huda kožna reakcija.
English: A total of 1,272 leukaemia patients received at least 1 dose of single-agent bosutinib.
Slovenian: Skupno 1.272 bolnikov z levkemijo je prejelo vsaj 1 odmerek bosutiniba kot samostojno zdravilo.
English: The secondary efficacy endpoints included MMR by 18 months, duration of MMR, CCyR by 12 months, duration of CCyR, event-free survival (EFS), and overall survival (OS).
Slovenian: Sekundarni opazovani dogodki učinkovitosti so vključevali MMR po 18 mesecih, trajanje MMR, CCyR po 12 mesecih, trajanje CCyR, preživetje brez dogodkov (EFS - Event-Free Survival) in celokupno preživetje (OS - Overall Survival).
English: What do you need to know before you take take Bosulif
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Bosulif
English: Return to chronic phase (RCP)=disappearance of features defining accelerated or blast phases but still in chronic phase.
Slovenian: Vrnitev v kronično fazo = izginotje značilnosti, ki določajo pospešeno ali blastno fazo, vendar je bolezen še vedno v kronični fazi.
English: If a dose is missed by more than 12 hours, take your next dose at your regular time on the following day.
Slovenian: Če ste pozabili vzeti odmerek in je minilo več kot 12 ur, vzemite naslednji odmerek ob običajnem času naslednji dan.
English: If you faint (loss of consciousness) or have an irregular heartbeat while taking Bosulif, tell your doctor immediately, as this may be a sign of a serious heart condition.
Slovenian: Če med jemanjem zdravila Bosulif omedlite (izgubite zavest) ali imate nereden srčni utrip, nemudoma obvestite zdravnika, saj je to lahko znak resne bolezni srca.
English: Foetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental transfer study in gravid Sprague-Dawley rats.
Slovenian: Izpostavljenost ploda radioaktivno označenemu bosutinibu med nosečnostjo je bila dokazana v študiji prenosa prek posteljice na brejih podganah Sprague-Dawley.
English: Effects of other medicinal products on bosutinib
Slovenian: Vpliv drugih zdravil na bosutinib
English: Transaminase elevations generally occurred early in the course of treatment (of the patients who experienced transaminase elevations of any grade, > 80% experienced their first event within the first 3 months).
Slovenian: Vrednosti transaminaz so se običajno povečale zgodaj po začetku zdravljenja (pri > 80 % bolnikov, pri katerih je prišlo do povečanih vrednosti transaminaz katerekoli stopnje, je do prvega dogodka prišlo v prvih treh mesecih).
English: 9/L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% basophils in peripheral blood, and no extramedullary involvement.
Slovenian: 9/l, odsotnost blastocitov ali promielocitov v periferni krvi, manj kot 5 % mielocitov + metamielocitov v kostnem mozgu, manj kot 20 % bazofilcev v periferni krvi in odsotnost ekstramedularnih dejavnikov.
English: Dispose unused medicinal product in accordance with local requirements.
Slovenian: Neuporabljeno zdravilo zavrzite v skladu z lokalnimi predpisi.
English: These adverse reactions are presented by system organ class and frequency.
Slovenian: Neželeni učinki so našteti glede na organski sistem in pogostnost.
English: Patients with diarrhoea and vomiting should be managed using standard-of-care treatment, including an antidiarrhoeal or antiemetic medicinal product and/or fluid replacement.
Slovenian: Bolnike z diarejo in bruhanjem je treba obravnavati z uporabo standardnega zdravljenja, ki vključuje antidiaroike ali antiemetike in/ali nadomeščanje tekočine.
English: Cytogenetic Response criteria: Major Cytogenetic Response included Complete [0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridisation (FISH)] or partial (1%-35%) cytogenetic responses.
Slovenian: Merila za citogenetski odziv: pomembni citogenetski odziv je vključeval popolne (0 % Ph+ metafaz iz kostnega mozga ali < 1 % pozitivnih celic iz fluorescenčne “in situ” hibridizacije [FISH]) ali delne (1 %-35 %) citogenetske odzive.
English: - if you suffer from bleeding problems.
Slovenian: - Če imate težave s krvavitvami.
English: However, if a patient taking bosutinib experiences dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely, the patient should refrain from these activities for as long as the undesirable effects persist.
Slovenian: Vendar če se pri bolniku med jemanjem bosutiniba pojavijo omotica, utrujenost, motnje vida ali drugi neželeni učinki, ki bi lahko vplivali na sposobnost vožnje ali upravljanja strojev, bolnik ne sme opravljati teh dejavnosti, vse dokler so prisotni neželeni učinki.
English: Patients will be carefully checked by their doctor for signs of this infection before treatment is started.
Slovenian: Pred začetkom zdravljenja bo zdravnik bolnike skrbno pregledal glede znakov te okužbe.
English: - Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.
Slovenian: - Ne uporabljajte tega zdravila, če opazite, da je ovojnina poškodovana ali da je že bila odprta.
English: - Do not use this medicine after the expiry date which is stated on the blister foil and carton after “EXP”.
Slovenian: - Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake “EXP / Uporabno do”.
English: After a minimum of 12 months of follow-up in the mITT population, 77.6% of patients treated with bosutinib (N=241) and 72.4% of patients treated with imatinib (N=239) were still receiving first-line treatment.
Slovenian: Po najmanj 12 mesecih spremljanja v populaciji mITT je 77,6 % bolnikov, ki so se zdravili z bosutinibom (n = 241), in 72,4 % bolnikov, ki so se zdravili z imatinibom (n = 239), še vedno prejemalo zdravljenje v prvi liniji.
English: FISH analysis (≥ 200 cells) could be used for post-baseline cytogenetic assessments if ≥ 20 metaphases were not available.
Slovenian: Analizo FISH (≥ 200 celic) je bilo mogoče uporabiti za poznejše citogenetske ocene v primeru, da ne bi bilo na voljo ≥ 20 metafaz.
English: If bosutinib is used during pregnancy, or the patient becomes pregnant while taking bosutinib, she should be apprised of the potential hazard to the foetus.
Slovenian: Če se bosutinib uporablja v času nosečnosti ali če bolnica zanosi med jemanjem bosutiniba, jo je treba seznaniti z možno nevarnostjo za plod.
English: Table 3 - Summary of MMR at Months 12 and 18 and CCyR by Month 12, by treatment group in the mITT population
Slovenian: Preglednica 3 - Povzetek MMR po 12 in 18 mesecih ter CCyR po 12 mesecih po skupini zdravljenja v populaciji mITT
English: Side effects with Bosulif may include:
Slovenian: Neželeni učinki pri jemanju zdravila Bosulif lahko vključujejo:
English: In vitro testing indicated that bosutinib had limited activity against the T315I or the V299L mutation.
Slovenian: Testiranje in vitro je pokazalo, da ima bosutinib omejeno aktivnost proti mutacijama T315I in V299L.
English: Four patients (0.3%) experienced QTcF interval prolongation (greater than 500 ms).
Slovenian: Pri 4 bolnikih (0,3 %) se je pojavilo podaljšanje QTcF (večje od 500 ms).
English: Bosutinib is not recommended for use during pregnancy, or in women of childbearing potential not using contraception.
Slovenian: Bosutiniba ni priporočljivo uporabljati med nosečnostjo ali pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
English: Also tell your doctor if you are losing weight or have experienced swelling of your feet, ankles, legs, hands or face.
Slovenian: Prav tako obvestite zdravnika, če izgubljate telesno maso ali če vam otekajo stopala, gležnji, noge, dlani ali obraz.
English: Table 5 - Efficacy results in previously treated patients with chronic and advanced phase CML*
Slovenian: Preglednica 5 - Rezultati učinkovitosti pri predhodno zdravljenih bolnikih s KML v kronični in napredovali fazi*
English: Patients with serum creatinine > 1.5 × ULN were excluded from the CML studies.
Slovenian: Bolniki s serumskim kreatininom > 1,5-kratnik ZMN so bili iz študij KML izključeni.
English: White opaque 3-ply PVC/Polychlorotrifluoroethene/PVC blister sealed with push-through foil backing containing either 14 or 15 tablets.
Slovenian: Bel, neprozoren, troslojen pretisni omot iz PVC/poliklorotrifluoroetena/PVC, zapečaten s folijo na potisk, ki vsebuje 14 ali 15 tablet.
English: Treatment with bosutinib is associated with diarrhoea and vomiting; therefore, patients with recent or ongoing clinically significant gastrointestinal disorder should use this medicinal product with caution and only after a careful benefit-risk assessment as respective patients were excluded from the clinical studies.
Slovenian: Zdravljenje z bosutinibom je povezano z diarejo in bruhanjem, zato je pri bolnikih z nedavno ali obstoječo klinično pomembno boleznijo prebavil to zdravilo treba uporabljati previdno in šele po skrbni oceni koristi in tveganj, saj so bili ti bolniki iz kliničnih študij izključeni.
English: Dose reductions are recommended for severe or persistent neutropenia and thrombocytopenia as described in Table 1:
Slovenian: Zmanjšanje odmerkov je priporočljivo pri hudi ali dolgotrajni nevtropeniji in trombocitopeniji, kot je opisano v preglednici 1:
English: Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL expressed in murine myeloid cell lines.
Slovenian: Bosutinib je zaviral 16 od 18 oblik BCR-ABL, odpornih na imatinib, izraženih v mieloidnih celičnih linijah glodavcev.
English: Do not breast-feed during treatment with Bosulif as it could harm your baby.
Slovenian: Med zdravljenjem z zdravilom Bosulif ne smete dojiti, kajti to lahko škoduje vašemu otroku.
English: Bosutinib (N=246)
Slovenian: odziv bosutinib (n = 246)
English: All 3 metabolites exhibited activity that was  5% that of bosutinib in a Src-transformed fibroblast anchorage-independent proliferation assay.
Slovenian: Vsi 3 presnovki so izkazovali aktivnost, ki je znašala  5 % aktivnosti bosutiniba pri Src-preoblikovanem preskusu sidriščno neodvisnega razraščanja fibroblastov.
English: Cytochrome P-450 (CYP)3A inhibitors
Slovenian: Zaviralci citokroma P-450 (CYP)3A
English: Bosutinib activity in vitro in hERG assays suggested a potential for prolongation of cardiac ventricular repolarisation (QTc).
Slovenian: Aktivnost bosutiniba pri hERG testih in vitro kaže na možnost podaljšanja repolarizacije srčnih ventriklov (QTc).
English: Paediatric population Bosulif has not yet been studied in children and adolescents less than 18 years of age.
Slovenian: Pediatrična populacija Zdravila Bosulif še niso raziskovali pri otrocih in mladostnikih, mlajših od 18 let.
English: Bosulif will only be prescribed to you by a doctor with experience in medicines to treat leukaemia.
Slovenian: Zdravilo Bosulif vam lahko predpiše le zdravnik, ki ima izkušnje z zdravili za zdravljenje levkemije.
English: If dose is missed by less than 12 hours, take your recommended dose.
Slovenian: Če ste pozabili vzeti odmerek in je minilo manj kot 12 ur, vzemite priporočeni odmerek.
English: Elevations of transaminases, particularly in the setting of concomitant increases in bilirubin, may be an early indication of drug-induced liver injury and these patients should be managed appropriately (see sections 4.2 and 4.8).
Slovenian: Povečane vrednosti transaminaz, še zlasti ob sočasnem povečanju vrednosti bilirubina, so lahko zgodnji znak z zdravilom povzročenih poškodb jeter; te bolnike je treba ustrezno obravnavati (glejte poglavji 4.2 in 4.8).
English: The percentage is based on number of patients with baseline mutation assessment.
Slovenian: Odstotek temelji na številu bolnikov z oceno mutacij na začetku študije.
English: Other medicines and Bosulif
Slovenian: Druga zdravila in zdravilo Bosulif
English: Discontinuations due to suboptimal response or treatment failure as assessed by the investigator occurred for 2.0% of patients in the bosutinib-treated group compared to 6.3% of patients in the imatinib-treated group.
Slovenian: Do prekinitev zaradi suboptimalnega odziva ali neuspešnega zdravljenja po presoji raziskovalca je prišlo pri 2,0 % bolnikov v skupini, ki se je zdravila z bosutinibom, v primerjavi s 6,3 % bolnikov iz skupine, ki se je zdravila z imatinibom.
English: The median time to CCyR (responders only) was 23.9 weeks in the bosutinib group compared to the 24.3 weeks imatinib group.
Slovenian: Mediani čas do CCyR (samo odzivni bolniki) je bil 23,9 tedna v skupini z bosutinibom v primerjavi s 24,3 tedna v skupini z imatinibom.
English: Following administration of a single dose of bosutinib (500 mg) with food in healthy subjects, the absolute bioavailability was 34%.
Slovenian: Po zaužitju enkratnega odmerka bosutiniba (500 mg) skupaj s hrano pri zdravih preskušancih je bila absolutna biološka uporabnost 34 %.
English: Vomiting or diarrhoea may reduce the effectiveness of oral contraceptives.
Slovenian: Bruhanje in driska lahko zmanjšata učinkovitost peroralnih kontraceptivov.
English: Bosulif is not to be used during pregnancy, unless clearly necessary, because Bosulif could harm an unborn baby.
Slovenian: Zdravila Bosulif se ne sme uporabljati med nosečnostjo, razen če je to nujno potrebno, saj lahko škoduje nerojenemu otroku.
English: Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
Slovenian: Razmisliti je treba o uporabi kratkodelujočih antacidov kot alternativi za PPIs; če je le mogoče, mora biti čas jemanja bosutiniba in antacidov ločen (npr. bosutinib zjutraj in antacidi zvečer).
English: Bosutinib inhibits the abnormal BCR-ABL kinase that promotes CML.
Slovenian: Bosutinib zavira nenormalno kinazo BCR-ABL, ki pospešuje KML.
English: The antiemetic agent, domperidone, has the potential to increase QT interval (QTc) prolongation and to induce “torsade de pointes”- arrhythmias; therefore, co-administration with domperidone should be avoided.
Slovenian: Antiemetik domperidon lahko podaljša interval QT (QTc) in povzroči aritmijo “torsade de pointes”, zato se je treba sočasni uporabi z domperidonom izogibati.
English: Bosutinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity, and photoxicity studies.
Slovenian: Zdravilo Bosulif so ocenjevali v študijah farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, vpliva na sposobnost razmnoževanja in fototoksičnosti.
English: Grapefruit products, including grapefruit juice and other foods that are known to inhibit CYP3A should be avoided (see section 4.5).
Slovenian: Izogibati se je treba izdelkom iz grenivke, vključno z grenivkinim sokom, ter drugi hrani, za katero je znano, da zavira CYP3A (glejte poglavje 4.5).
English: Very common Lipase increased (including Hyperlipasaemia) Common
Slovenian: Preiskave zelo pogosti povečane vrednosti lipaze (vključno s hiperlipazemijo)
English: Patients with uncontrolled or significant cardiovascular disease including QTc prolongation, at baseline, were not included in clinical studies (see sections 5.1 and 5.3).
Slovenian: Bolniki, ki so imeli na začetku študije nenadzorovano ali hudo bolezen srca, vključno s podaljšanjem QTc, niso bili vključeni v klinične študije (glejte poglavji 5.1 in 5.3).
English: Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 17
Slovenian: Imetnik dovoljenja za promet z zdravilom Pfizer Europe MA EEIG Boulevard de la Plaine 17
English: Reactivation of hepatitis B (HBV) in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL TKIs.
Slovenian: Pri bolnikih, ki so kronični prenašalci tega virusa, se je pojavila reaktivacija hepatitisa B (HBV), potem ko so ti bolniki prejeli zaviralce tirozin-kinaze BCR-ABL.
English: In in vitro studies, bosutinib inhibits proliferation and survival of established CML cell lines, Ph+ ALL cell lines, and patient-derived primary primitive CML cells.
Slovenian: V študijah in vitro bosutinib zavira proliferacijo in preživetje trajnih celičnih linij KML, celičnih linij Ph+ ALL in primarnih, primitivnih celic KML, pridobljenih od bolnikov.
English: Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE14.
Slovenian: Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), zaviralci proteinskih kinaz; oznaka ATC: L01XE14
English: Bosulif film-coated tablets come in different strengths.
Slovenian: Bosulif filmsko obložene tablete so na voljo v različnih jakostih.
English: Mutation assessed No mutation At least 1 mutation Dasatinib resistant mutations E255K/V F317L Nilotinib resistant mutations c
Slovenian: mutacija ocenjena ni mutacije vsaj 1 mutacija mutacije, neodzivne na dasatinib E255K/V F317L mutacije, neodzivne na nilotinib Y253H E255K/V F359C/I/V
English: Table 2 - Adverse reactions for bosutinib
Slovenian: Preglednica 2 - Neželeni učinki bosutiniba
English: Bosutinib was highly bound to human plasma proteins in vitro (94%) and ex vivo in healthy subjects (96%), and binding was not concentration-dependent.
Slovenian: Bosutinib se je in vitro (94 %) ter ex vivo pri zdravih preskušancih (96 %) v veliki meri vezal na človeške plazemske beljakovine; vezava ni bila odvisna od koncentracije.
English: Cytogenetic responses were based on the percentage of Ph+ metaphases among ≥ 20 metaphase cells in each bone marrow sample.
Slovenian: Citogenetski odzivi so temeljili na odstotku Ph+ metafaz med ≥ 20 metafaznih celic v vsakem vzorcu kostnega mozga.
English: Chest pain (including Chest discomfort), Pain
Slovenian: pogosti bolečina v prsnem košu (vključno s tiščanjem v prsnem košu), bolečina
English: Bosutinib belongs to a pharmacological class of medicinal products known as kinase inhibitors.
Slovenian: Bosutinib sodi v farmakološko skupino zdravil, imenovanih zaviralci kinaze.
English: The data from this study indicate that bosutinib does not prolong the QTc in healthy subjects at the dose of 500 mg daily with food, and under conditions that give rise to supratherapeutic plasma concentrations.
Slovenian: Podatki iz študije kažejo, da bosutinib pri zdravih preskušancih, ki so prejemali odmerek 500 mg na dan skupaj s hrano, in v okoliščinah, ki povzročijo supraterapevtske plazemske koncentracije, ne podaljša QTc.
English: Women taking Bosulif will be advised to use effective contraception during treatment and for at least 1 month after the last dose.
Slovenian: Ženskam, ki jemljejo zdravilo Bosulif, je treba svetovati, naj med zdravljenjem in še vsaj 1 mesec po zadnjem odmerku uporabljajo učinkovito metodo kontracepcije.
English: This finding was in a study of bosutinib in combination with letrozole in a patient with metastatic breast cancer.
Slovenian: Do te ugotovitve je prišlo v študiji bosutiniba v kombinaciji z letrozolom pri bolnici z metastatskim rakom dojk.
English: In a mass-balance study with oral bosutinib, an average of 94.6% of the total dose was recovered in 9 days; faeces (91.3%) was the major route of excretion, with 3.29% of the dose recovered in urine.
Slovenian: V študiji masne porazdelitve peroralno zaužitega bosutiniba se je povprečno 94,6 % celotnega odmerka izločilo v 9 dneh; glavna pot izločanja je bila blato (91,3 %), medtem ko se je z urinom izločilo 3,29 % odmerka.
English: It is unknown whether bosutinib and its metabolites are excreted in human milk.
Slovenian: Dojenje Ni znano, ali se bosutinib in njegovi presnovki izločajo v materino mleko.
English: Bosutinib treatment reduced the size of CML tumours growing in nude mice and inhibited growth of murine myeloid tumours expressing imatinib-resistant forms of BCR-ABL. Bosutinib also inhibits receptor tyrosine kinases c-Fms, EphA and B receptors, Trk family kinases, Axl family kinases, Tec family kinases, some members of the ErbB family, the non-receptor tyrosine kinase Csk, serine/threonine kinases of the Ste20 family, and 2 calmodulin-dependent protein kinases.
Slovenian: Zdravljenje z bosutinibom je zmanjšalo velikost tumorjev KML, ki so rasli na golih miših, ter pri glodavcih zaviralo rast mieloidnih tumorjev, ki so izražali na imatinib odporne oblike BCR-ABL. Bosutinib zavira tudi receptorske tirozin-kinaze c-Fms, receptorje EphA in EphB, kinaze iz družine Trk, kinaze iz družine Axl, kinaze iz družine Tec, nekatere člane družine ErbB, nereceptorske tirozin-kinaze Csk, serin/treonin-kinaze iz družine Ste20 in 2 proteinski kinazi, odvisni od kalmodulina.
English: Statistically significant comparison at the pre-specified significance level; based on CMH test stratified by geographical region and Sokal score at randomisation.
Slovenian: Statistično pomembna primerjava pri vnaprej določeni stopnji pomembnosti; na osnovi testa CMH, stratificiranega po geografski regiji in oceni po Sokalu ob randomizaciji.
English: If you have any further questions on the use of this medicine ask your doctor or pharmacist.
Slovenian: Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali farmacevtom.
English: Pfizer ApS Tlf: +45 44 20 11 00
Slovenian: Danmark Pfizer ApS Tlf: +45 44 20 11 00
English: In particular, you should ask your doctor if you want to use a medicine containing domperidone for the treatment of nausea and/or vomiting.
Slovenian: Še zlasti se posvetujte z zdravnikom, če želite jemati zdravilo proti siljenju na bruhanje in/ali bruhanju, ki vsebuje domperidon.
English: Females were observed with increased embryonic resorptions, and decreases in implantations and viable embryos.
Slovenian: Pri samicah so opazili povečanje resorpcije zarodkov in zmanjšanje števila implantacij in zarodkov, sposobnih za življenje.
English: Men being treated with bosutinib are advised to seek advice on conservation of sperm prior to treatment because of the possibility of decreased fertility due to therapy with bosutinib.
Slovenian: Moškim, ki se zdravijo z bosutinibom, je treba svetovati, naj se pred začetkom zdravljenja posvetujejo glede shranjevanja sperme, ker obstaja možnost zmanjšanja plodnosti zaradi zdravljenja z bosutinibom.
English: In a study in liver impaired subjects, an increasing frequency of QTc prolongation > 450 ms with declining hepatic function was observed.
Slovenian: V študiji pri preskušancih z okvarjenim delovanjem jeter so opazili povečano pogostnost podaljšanja QTc za > 450 ms skupaj z zmanjševanjem delovanja jeter.
English: Caution is recommended in patients with previous history of pancreatitis.
Slovenian: Pri bolnikih z anamnezo pankreatitisa priporočajo previdnost.
English: At Months 3, 6, and 9, the proportion of patients with MMR was higher in the bosutinib treatment group compared to the imatinib treatment group (Table 4).
Slovenian: Po 3, 6 in 9 mesecih je bil delež bolnikov z MMR večji v skupini, ki se je zdravila z bosutinibom, kot v skupini, ki se je zdravila z imatinibom (preglednica 4).
English: The median duration of therapy was 14.1 months (range: 0.3 to 24.7 months), 61.6 months (0.03 to 99.6 months), 11.1 months (range: 0.03 to 123.3 months), 30.2 months (range: 0.3 to 85.6 months), and 5.7 months (range: 0.07 to 17.8 months), respectively.
Slovenian: Mediano trajanje zdravljenja je bilo 14,1 meseca (razpon: 0,3 do 24,7 meseca), 61,6 meseca (0,03 do 99,6 meseca), 11,1 meseca (razpon: 0,03 do 123,3 meseca), 30,2 meseca (razpon: 0,3 do 85,6 meseca) in 5,7 meseca (razpon: 0,07 do 17,8 meseca), upoštevajoč vrstni red študij v prejšnjem stavku.